It would probably be good to touch on:
- To what degree we can attribute these results to Bisantrene (over Clofarabine and Fludarabine).
- Comparison response rates seen in other anti-cancer P2 drugs that go on to get picked up by BP
- Can we expect RC220 to have similar efficacy, or perhaps fewer adverse events (lower risk of infection)?
- Highlight the curious lack of cardiotoxicity despite Clofarabine being highly cardiotoxic!
- Any exploratory, or circumstantial FTO insights - pretty please
- Try to include some $$$ numbers - this needs to appeal to all investors, not just the altruistic
ASH2023 - Sheba 2.0, page-51
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.100(6.45%) |
Mkt cap ! $274.5M | |||
| Open | High | Low | Value | Volume |
| $1.65 | $1.75 | $1.61 | $687.0K | 410.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3047 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 18354 | 2 |
View Market Depth
| Last trade - 16.10pm 14/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.67 |
Change
0.100 ( 8.61 %) |
||||
| Open | High | Low | Volume | ||
| $1.64 | $1.73 | $1.63 | 33428 | ||
| Last updated 15.54pm 14/05/2024 ? | |||||
| RAC (ASX) Chart |